Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin

BACKGROUND: The adverse impact of increasing brain tumor size on the efficacy of antibody-drug conjugates (ADCs) was investigated preclinically then validated with clinical data. METHODS—PRECLINICAL STUDY: The impact of tumor size on ADC tumor delivery and treatment response was evaluated in an EGFR...

Descripción completa

Detalles Bibliográficos
Autores principales: Gan, Hui K, Parakh, Sagun, Lassman, Andrew B, Seow, Aidan, Lau, Eddie, Lee, Sze Ting, Ameratunga, Malaka, Perchyonok, Yuliya, Cao, Diana, Burvenich, Ingrid J G, O’Keefe, Graeme J, Rigopoulos, Angela, Gomez, Erica, Maag, David, Scott, Andrew M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Basic and Translational Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446913/
https://www.ncbi.nlm.nih.gov/pubmed/34549181
http://dx.doi.org/10.1093/noajnl/vdab102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446913/
https://www.ncbi.nlm.nih.gov/pubmed/34549181
http://dx.doi.org/10.1093/noajnl/vdab102

Ejemplares similares